AT A GLANCE
TrueBinding Inc. is an early stage biotherapeutics development company focused on creating new and exciting molecules for applications in immuno oncology and other disease areas with great unmet medical need.
Based on the application of the TruebindingTM platform, TrueBinding has to date discovered 6 novel ligands, previously uncharacterized, to receptors of known checkpoint inhibitor pathways.
As compared to traditional approaches such as membrane protein library screening,
Our proprietary technology is proven to be powerful to discover new targets and their binding partners. And we can verify them by vary assays
Currently, the lead program has multiple components with respect to data; the proof and characterization of a new ligand for Tim-3 along with the antibody development and demonstration of activity in in vivo tumor models.
Earlier programs are at various stages of development, focusing on therapeutic antibody generation to block our newly discovered checkpoint inhibitor interactions
Dr. Dongxu Sun
Co-founder & CEO
PhD, University of Minnesota. Postdoc, Cornell Medical College. Project Scientist, Cleveland Clinic.
Worked at ImmuNext,
Successfully identified new protein binding partners in novel signaling pathways of IFNg.
MD. Peter Traber
Ex. President and CEO of Galetin Therapeutics
President and CEO of Baylor College of Medicine
SVP and CMO at GSK.
Dean of UPenn Medical Schcool
Dr. Fan Chen
SVP of Biologics and CMC
20+ years experience in bioprocess development
. VP of Process Development at LakePharma,
Senior leader of process development at Dendreon/MedImmune/
For any inquiries, questions or commendations, please fill out the following form
Senior Scientist/Scientist Immune Oncology
We are seeking a highly motivated individual with experience in immunology or related fields to join us at this exciting moment. The primary focus of the job is identification and characterization of novel targets and contribution in the development of new drugs for cancer immunotherapy and other disease indications.
Education and Experience:
Ph.D, or Master with 5-year working experience in Immunology or related fields.
Expertise in ex vivo assays assessing various immune populations, including T cells, macrophages, and DCs
Experience in in vivo mouse tumor models is a plus
Expertise in multi-color (>5 color) flow cytometer
A willingness to learn and adopt new experimental skills as needed.
If interested, please contact Dr. Sun at
Dr. Mark Selby
Inventor of Ipilimumab and Nivolumab
Senior director at BMS
Associated director at Medarex,
MD. Mitchel Berger
Chair of neurological surgery department at UCSF
Director of the Brain Tumor Research Center
President, American Association of Neurological Surgeons
President, American Academy of Neurological Surgery
Professor Debbie Thurmond
Key opinion leader in the field of Diabetes and Metabolism.
Founding Chair of the Department of Molecular & Cellular Endocrinology at the City of Hope Beckman Research Institute
Deputy Director of the Diabetes & Metabolism Research Institute